BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, and HemaCare Corporation, a leading supplier of blood derived cells and components for research and clinical applications, has entered into a strategic alliance wherein HemaCare will market BioLife’s HypoThermosol and CryoStor biopreservation media products and HemaCare’s blood derived cells to the research and clinical communities.

Pete van der Wal, president and CEO of HemaCare, remarked on the extended shelf life and viability of HemaCare’s Bioresearch products, specifically, peripheral blood mononuclear cells (PBMNC’s), through the use of BioLife’s HypoThermosol storage and shipping medium; “the current gold standard of shipping frozen PBMNC’s to researchers requires back-end thawing and culturing before the cells are ready for use. HypoThermosol has demonstrated remarkable ability to extend the shelf life of this valuable cell type out to 4 days, eliminating the cryopreservation process and its related yield loss, and enabling a worldwide delivery footprint for fresh apheresis-derived cells.”

Mike Rice, BioLife Solutions president and CEO, commented on the announcement by stating, “HemaCare offers best in class bioresearch products derived from the most robust and highest quality apheresis collections. We’re glad to partner with them to enable a new product option for their customers. We look forward to additional collaborative research that we believe will generate even more data supporting the value proposition of our proprietary biopreservation media products.”